Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients
Condition: Inflammatory Bowel Disease (IBD)
MeSH terms: Intestinal Diseases; Inflammatory Bowel Diseases
Study type: Observational

Summary: 
      The investigators proposed study is the first of its kind. The investigators will measure
      measles, mumps, rubella, tetanus, diphtheria and pertussis antibodies in patients on the
      current IBD treatment modalities and compare the vaccine antibody concentrations and
      correlate them with time since immunization.
    

Detailed description: 
      Tetanus and diphtheria have become rare diseases because of widespread immunization that
      began during World War II. The percentage of people who got pertussis (whooping cough) also
      went down after vaccination, but large outbreaks have occurred over the past decade. Measles,
      mumps, rubella (German measles) and varicella (chicken pox) are illnesses that resolve
      quickly, but which can cause other diseases to take hold or get worse. Routine vaccination
      can prevent infection and has been and recommended for use in the United States beginning in
      the 1960s and 1970s; and in 1995 for varicella. Today measles, mumps, and rubella are
      especially uncommon in the U.S. thanks to vaccination programs; and the percentage of people
      with varicella is going down. Despite widespread vaccination efforts, there have been recent
      outbreaks of measles and mumps in the U.S., in part because these diseases are still common
      in other parts of the world.

      Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal
      tract which includes Crohn's disease (CD) and ulcerative colitis (UC). Treatment options for
      IBD consist of immunosuppressive therapy, meaning that the drugs weaken the immune system,
      such as systemic corticosteroids, immunomodulators (thiopurines and methotrexate) and/or
      biologics, such as tumor necrosis factor alpha (TNF) agents or an integrin inhibitor
      (vedolizumab). Patients with IBD can achieve clinical remission and decrease the risk of
      complications with treatment; however, treatment can also increase the risk for infections
      because they weaken the immune system. Some of these infections are preventable with routine
      vaccination.

      You are invited to take part in this research project to determine if people with IBD on
      different types of therapy have a lower amount of antibodies than healthy individuals.
      Antibodies are proteins used by the immune system to attack viruses like tetanus and measles.
      Antibodies can be introduced into the body through vaccines. The fewer antibodies there are,
      the harder it is for the antibodies to attack a virus, meaning that the person could get sick
      with a virus. This research project will help us figure out whether people with IBD have
      fewer antibodies than people without IBD. The investigators will also look at whether the
      type of treatment people take for IBD affects the amount of antibodies. T

      This will tell us who is more likely to get sick from viruses, and why. The investigators
      will recruit 90 IBD patients under treatment for their IBD as well as 20 healthy controls for
      a total of 110 patients at the University of Wisconsin Hospital & Clinics.
    

Intervention name(s): Blood Draw/Data Collection
Intervention type(s): Procedure
Intervention description(s): Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
Observational model: Other
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        The subject population will consist of individuals with inflammatory bowel disease and
        healthy controls.
      
Biospecimen description: 
      Blood sample to measure antibody concentration